XML 23 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue Components
 3 Months Ended
Jun. 30, 2021
Revenue from Contract with Customer [Abstract]  
Revenue Components Revenue Components
The following table provides information about the Company’s revenues (in thousands):
Three Months Ended June 30,
20212020
Revenues:
Product revenue, net:
ORGOVYX$10,479 $— 
MYFEMBREE1,075 — 
Total product revenue, net11,554 — 
Pfizer collaboration revenue:
Amortization of upfront payment20,974 — 
Amortization of regulatory milestone8,535 — 
Total Pfizer collaboration revenue29,509 — 
Richter license and milestone revenue— 33,333 
Total revenues$41,063 $33,333 
The Company began generating product revenue from sales of ORGOVYX and MYFEMBREE in the U.S. in January 2021 and June 2021, respectively. The Company records product revenue net of estimated discounts, chargebacks, rebates, product returns, and other gross-to-net revenue deductions.
Pfizer collaboration revenue for the three months ended June 30, 2021 consists of the partial recognition of the upfront payment the Company received from Pfizer in December 2020 and of the regulatory milestone payment due from Pfizer that was triggered upon the FDA approval of MYFEMBREE for the management of heavy menstrual bleeding associated with uterine fibroids on May 26, 2021. There were no such amounts recognized for the three months ended June 30, 2020.
There was no Richter license and milestone revenue for the three months ended June 30, 2021. Richter license and milestone revenue for the three months ended June 30, 2020 consists of the partial recognition of the upfront payment the Company received from Richter in March 2020 and the regulatory milestone payment the Company received from Richter in April 2020.
See Note 8 for additional information regarding collaboration revenue under the Pfizer Collaboration and License Agreement and license and milestone revenue under the Richter Development and Commercialization Agreement.